Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 568

1.

Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients.

Frasson AL, Lichtenfels M, de Souza AAB, Vollbrecht B, Falcone AB, Frasson MARM, Barbosa F.

Breast Cancer Res Treat. 2020 Mar 25. doi: 10.1007/s10549-020-05582-w. [Epub ahead of print]

PMID:
32215763
2.

Clinical and economic effect of administration of red blood product transfusions in an outpatient supportive care cancer service.

Sbrana A, Paolieri F, Bloise F, Danova M, Galli L, Brunetti IM, Vasile E, Ricci S, Falcone A, Antonuzzo A.

Biomed Rep. 2020 Apr;12(4):199-203. doi: 10.3892/br.2020.1274. Epub 2020 Feb 10.

3.

A Model of a Zebrafish Avatar for Co-Clinical Trials.

Usai A, Di Franco G, Colucci P, Pollina LE, Vasile E, Funel N, Palmeri M, Dente L, Falcone A, Morelli L, Raffa V.

Cancers (Basel). 2020 Mar 13;12(3). pii: E677. doi: 10.3390/cancers12030677.

4.

Immune profiling of deficient mismatch repair colorectal cancer (dMMR CRC) tumor microenvironment reveals different levels of immune system activation.

Giannini R, Zucchelli G, Giordano M, Ugolini C, Moretto R, Ambryszewska K, Leonardi M, Sensi E, Morano F, Pietrantonio F, Cremolini C, Falcone A, Fontanini G.

J Mol Diagn. 2020 Mar 12. pii: S1525-1578(20)30052-0. doi: 10.1016/j.jmoldx.2020.02.008. [Epub ahead of print]

PMID:
32173570
5.

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.

Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators.

Lancet Oncol. 2020 Mar 9. pii: S1470-2045(19)30862-9. doi: 10.1016/S1470-2045(19)30862-9. [Epub ahead of print]

PMID:
32164906
6.

Immune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist?

Vivaldi C, Catanese S, Massa V, Pecora I, Salani F, Santi S, Lencioni M, Vasile E, Falcone A, Fornaro L.

Int J Mol Sci. 2020 Feb 28;21(5). pii: E1658. doi: 10.3390/ijms21051658. Review.

7.

Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications.

Cacciato Insilla A, Vivaldi C, Giordano M, Vasile E, Cappelli C, Kauffmann E, Napoli N, Falcone A, Boggi U, Campani D.

Front Oncol. 2020 Feb 7;10:64. doi: 10.3389/fonc.2020.00064. eCollection 2020.

8.

Longitudinal evaluation of angiogenesis-related circulating biomarkers during second-line treatment with paclitaxel and ramucirumab in advanced gastroesophageal cancer.

Fornaro L, Vivaldi C, Orlandi P, Musettini G, Pecora I, Gentile D, Catanese S, Lencioni M, Salani F, Pasquini G, Massa V, Di Desidero T, Falcone A, Vasile E, Bocci G.

Ann Oncol. 2019 Jul;30 Suppl 4:iv88. doi: 10.1093/annonc/mdz155.318. Epub 2019 Dec 4. No abstract available.

9.

Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients.

Catanese S, Aringhieri G, Cappelli C, Vivaldi C, Vitali S, Pecora I, Salani F, Pasquini G, Balducci F, Piercarlo R, Lencioni M, Vasile E, Massa V, Falcone A, Caramella D, Fornaro L.

Ann Oncol. 2019 Jul;30 Suppl 4:iv82. doi: 10.1093/annonc/mdz155.298. Epub 2019 Dec 4. No abstract available.

10.

Characterization of mismatch repair deficiency in biliary tract cancer.

Vivaldi C, Ugolini C, Orsi G, Formica V, Catanese S, Andrea C, Andrikou K, Doldo E, Pecora I, Campani D, Bonetti LR, Pasquini G, Salani F, Massa V, Niccoli C, Lencioni M, Vasile E, Gardini AC, Fornaro L, Fontanini G, Cascinu S, Falcone A.

Ann Oncol. 2019 Jul;30 Suppl 4:iv76. doi: 10.1093/annonc/mdz155.278. Epub 2019 Dec 4. No abstract available.

11.

Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable mCRC.

Cremolini C, Antoniotti C, Lonardi S, Rossini D, Morano F, Cordio S, Bergamo F, Marmorino F, Maiello E, Passardi A, Masi G, Tamburini E, Santini D, Grande R, Zaniboni A, Granetto C, Murgioni S, Aprile G, Delliponti L, Boni L, Falcone A.

Ann Oncol. 2019 Jul;30 Suppl 4:iv154. doi: 10.1093/annonc/mdz183.005. Epub 2019 Dec 4. No abstract available.

12.

Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC).

Argiles G, Margalef NM, Valladares-Ayerbes M, de Prado JV, Grávalos C, Alfonso PG, Santos C, Tobeña M, Sastre J, Benavides M, Cano T, Loupakis F, Garrote MR, Rivera F, Goldberg R, Falcone A, Bennouna J, Ciardiello F, Tabernero J, Aranda E.

Ann Oncol. 2019 Jul;30 Suppl 4:iv135. doi: 10.1093/annonc/mdz154.025. Epub 2019 Dec 4. No abstract available.

13.

Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies.

Zucchelli G, Marmorino F, Rossini D, Aprile G, Casagrande M, Lonardi S, Murgioni S, Dell'Aquila E, Tomasello G, Moretto R, Antoniotti C, Borelli B, Urbano F, Ronzoni M, Zaniboni A, Manglaviti S, Buonadonna A, Ritorto G, Masi G, Allegrini G, Falcone A, Cremolini C.

Ann Oncol. 2019 Jul;30 Suppl 4:iv130. doi: 10.1093/annonc/mdz154.012. Epub 2019 Dec 4. No abstract available.

14.

Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer.

Ducreux M, O'Connor J, Dochy E, Fiala-Buskies S, Cervantes A, Falcone A; N on behalf of the CORRELATE Investigators.

Ann Oncol. 2019 Jul;30 Suppl 4:iv119. doi: 10.1093/annonc/mdz156.028. Epub 2019 Dec 4. No abstract available.

15.

Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis.

Rossini D, Pagani F, Pellino A, Dell'Aquila E, Liscia N, Bensi M, Germani M, Masi G, Moretto R, Santini D, Salvatore L, Scartozzi M, Lonardi S, Zucchelli G, Puglisi F, Vannini F, Colombo C, Falcone A, Pietrantonio F, Cremolini C.

Ann Oncol. 2019 Jul;30 Suppl 4:iv118. doi: 10.1093/annonc/mdz156.026. Epub 2019 Dec 4. No abstract available.

16.

Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies.

Rossini D, Sbrana A, Bergamo F, Manai C, Santini D, Ghidini M, Antoniotti C, Moretto R, Marmorino F, Urbano F, Ronzoni M, Noventa S, Randon G, Carlomagno C, Latiano T, Cordio S, Granetto C, Cremolini C, Falcone A, Antonuzzo A.

Ann Oncol. 2019 Jul;30 Suppl 4:iv114-iv115. doi: 10.1093/annonc/mdz156.014. Epub 2019 Dec 4. No abstract available.

PMID:
32084980
17.

FLOaTing toward new standards in locally advanced resectable gastroesophageal cancer.

Fornaro L, Vivaldi C, Calvetti L, Cappetta A, Falcone A, Aprile G.

J Thorac Dis. 2019 Dec;11(12):5694-5700. doi: 10.21037/jtd.2019.12.103. No abstract available.

18.

Morphological and molecular characterization of Bertiella sp. (Cestoda, Anoplocephalidae) infection in a human and howler monkeys in Argentina.

Servián A, Zonta ML, Cociancic P, Falcone A, Ruybal P, Capasso S, Navone GT.

Parasitol Res. 2020 Feb 6. doi: 10.1007/s00436-020-06615-5. [Epub ahead of print]

PMID:
32025808
19.

Application of the ESR iGuide clinical decision support system to the imaging pathway of patients with hepatocellular carcinoma and cholangiocarcinoma: preliminary findings.

Gabelloni M, Di Nasso M, Morganti R, Faggioni L, Masi G, Falcone A, Neri E.

Radiol Med. 2020 Feb 4. doi: 10.1007/s11547-020-01142-w. [Epub ahead of print]

PMID:
32020528
20.

Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study.

Faloppi L, Puzzoni M, Casadei Gardini A, Silvestris N, Masi G, Marisi G, Vivaldi C, Gadaleta CD, Ziranu P, Bianconi M, Loretelli C, Demurtas L, Lai E, Giampieri R, Galizia E, Ulivi P, Battelli N, Falcone A, Cascinu S, Scartozzi M.

Target Oncol. 2020 Feb;15(1):115-126. doi: 10.1007/s11523-020-00698-x.

PMID:
32020517
21.

BRAF mutant metastatic colorectal cancers: new arrows in our quiver.

Cremolini C, Moretto R, Zucchelli G, Falcone A.

Ann Transl Med. 2019 Dec;7(Suppl 8):S367. doi: 10.21037/atm.2019.08.118. No abstract available.

22.

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab.

Pantano F, Russano M, Berruti A, Mansueto G, Migliorino MR, Adamo V, Aprile G, Gelibter A, Ficorella C, Falcone A, Russo A, Aieta M, Maio M, Martelli O, Barni S, Napolitano A, Roca E, Quadrini S, Iacono D, Russo A, Calvetti L, Occhipinti MA, Cortellini A, Vasile E, Passiglia F, Imperatori M, Calabrò L, Di Giacomo AM, Petrelli F, Pasquini G, Franchina T, Venditti O, Intagliata S, Galvano A, Fioroni I, Vincenzi B, Tonini G, Santini D.

Expert Opin Biol Ther. 2020 Mar;20(3):319-326. doi: 10.1080/14712598.2020.1724953. Epub 2020 Feb 6.

PMID:
32011207
23.

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.

Russo A, Russano M, Franchina T, Migliorino MR, Aprile G, Mansueto G, Berruti A, Falcone A, Aieta M, Gelibter A, Russo A, Barni S, Maio M, Martelli O, Pantano F, Iacono D, Calvetti L, Quadrini S, Roca E, Vasile E, Imperatori M, Occhipinti M, Galvano A, Petrelli F, Calabrò L, Pasquini G, Intagliata S, Ricciardi GRR, Tonini G, Santini D, Adamo V.

Adv Ther. 2020 Mar;37(3):1145-1155. doi: 10.1007/s12325-020-01229-w. Epub 2020 Jan 30.

PMID:
32002809
24.

Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer.

Moretto R, Falcone A, Cremolini C.

Int J Cancer. 2020 May 1;146(9):2652-2654. doi: 10.1002/ijc.32884. Epub 2020 Jan 29. No abstract available.

PMID:
31970766
25.

First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design.

André T, Saunders M, Kanehisa A, Gandossi E, Fougeray R, Amellal NC, Falcone A.

Future Oncol. 2020 Feb;16(4):21-29. doi: 10.2217/fon-2019-0786. Epub 2020 Jan 9.

26.

Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.

Yoshino T, Cleary JM, Van Cutsem E, Mayer RJ, Ohtsu A, Shinozaki E, Falcone A, Yamazaki K, Nishina T, Garcia-Carbonero R, Komatsu Y, Baba H, Argilés G, Tsuji A, Sobrero A, Yamaguchi K, Peeters M, Muro K, Zaniboni A, Sugimoto N, Shimada Y, Tsuji Y, Hochster HS, Moriwaki T, Tran B, Esaki T, Hamada C, Tanase T, Benedetti F, Makris L, Yamashita F, Lenz HJ.

Ann Oncol. 2020 Jan;31(1):88-95. doi: 10.1016/j.annonc.2019.10.005.

27.

Dedifferentiated liposarcoma: when eribulin can make the difference.

Sbrana A, Paolieri F, Bloise F, Manacorda S, Nuzzo A, Sammarco E, Galli L, Falcone A.

Future Oncol. 2020 Jan;16(1s):21-24. doi: 10.2217/fon-2019-0598. Epub 2019 Dec 24.

PMID:
31872768
28.

The 2019 TOPRA (Organization for Professionals in Regulatory Affairs) Annual Symposium (September 30-October 2, 2019 - Dublin, Ireland).

Falcone A, Fernández J.

Drugs Today (Barc). 2019 Oct;55(10):653-659. doi: 10.1358/dot.2019.55.10.3084505.

PMID:
31720562
29.

Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.

Ducreux M, Petersen LN, Öhler L, Bergamo F, Metges JP, de Groot JW, Wang JY, García Paredes B, Dochy E, Fiala-Buskies S, Cervantes A, O'Connor JM, Falcone A; CORRELATE Investigators.

Eur J Cancer. 2019 Dec;123:146-154. doi: 10.1016/j.ejca.2019.09.015. Epub 2019 Nov 4.

30.

Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients.

Catalano V, Bergamo F, Cremolini C, Vincenzi B, Negri F, Giordani P, Alessandroni P, Intini R, Stragliotto S, Rossini D, Borelli B, Santini D, Sarti D, Rocchi MBL, Lonardi S, Falcone A, Zagonel V, Mattioli R, Graziano F.

J Cancer Res Clin Oncol. 2020 Feb;146(2):493-501. doi: 10.1007/s00432-019-03077-w. Epub 2019 Nov 6.

PMID:
31691872
31.

Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses.

Lenz HJ, Argiles G, Yoshino T, Lonardi S, Falcone A, Limón ML, Sobrero A, Hastedt C, Peil B, Voss F, Griebsch I, Van Cutsem E.

Clin Colorectal Cancer. 2019 Dec;18(4):269-279.e5. doi: 10.1016/j.clcc.2019.08.005. Epub 2019 Sep 4.

32.

Evidence-based interventions cause multifold increase of influenza immunization rates in a free clinic.

Falcone AL, Vess J, Johnson E.

J Am Assoc Nurse Pract. 2019 Oct 1. doi: 10.1097/JXX.0000000000000302. [Epub ahead of print]

PMID:
31577666
33.

Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.

Marmorino F, Rossini D, Lonardi S, Moretto R, Zucchelli G, Aprile G, Dell'Aquila E, Ratti M, Bergamo F, Masi G, Urbano F, Ronzoni M, Libertini M, Borelli B, Randon G, Buonadonna A, Allegrini G, Pella N, Ricci V, Boccaccino A, Latiano TP, Cordio S, Passardi A, Tamburini E, Boni L, Falcone A, Cremolini C.

Ann Oncol. 2019 Dec 1;30(12):1969-1977. doi: 10.1093/annonc/mdz403.

PMID:
31573612
34.

Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan.

Fornaro L, Leone F, Vienot A, Casadei-Gardini A, Vivaldi C, Lièvre A, Lombardi P, De Luca E, Vernerey D, Sperti E, Musettini G, Satolli MA, Edeline J, Spadi R, Neuzillet C, Falcone A, Pasquini G, Clerico M, Passardi A, Buscaglia P, Meurisse A, Aglietta M, Brac C, Vasile E, Montagnani F.

Clin Colorectal Cancer. 2019 Dec;18(4):e394-e401. doi: 10.1016/j.clcc.2019.08.004. Epub 2019 Sep 4.

PMID:
31564556
35.

Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer.

Burzykowski T, Coart E, Saad ED, Shi Q, Sommeijer DW, Bokemeyer C, Díaz-Rubio E, Douillard JY, Falcone A, Fuchs CS, Goldberg RM, Hecht JR, Hoff PM, Hurwitz H, Kabbinavar FF, Koopman M, Maughan TS, Punt CJA, Saltz L, Schmoll HJ, Seymour MT, Tebbutt NC, Tournigand C, Van Cutsem E, de Gramont A, Zalcberg JR, Buyse M; Aide et Recherche en Cancerologie Digestive Group.

JAMA Netw Open. 2019 Sep 4;2(9):e1911750. doi: 10.1001/jamanetworkopen.2019.11750.

36.

Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.

Cantini L, Pistelli M, Merloni F, Fontana A, Bertolini I, De Angelis C, Bastianelli L, Della Mora A, Santinelli A, Savini A, Maccaroni E, Diodati L, Falcone A, Berardi R.

Clin Breast Cancer. 2020 Feb;20(1):e89-e98. doi: 10.1016/j.clbc.2019.06.008. Epub 2019 Jul 11.

PMID:
31378534
37.

Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.

Del Re M, Bertolini I, Crucitta S, Fontanelli L, Rofi E, De Angelis C, Diodati L, Cavallero D, Gianfilippo G, Salvadori B, Fogli S, Falcone A, Scatena C, Naccarato AG, Roncella M, Ghilli M, Morganti R, Fontana A, Danesi R.

Breast Cancer Res Treat. 2019 Nov;178(1):57-62. doi: 10.1007/s10549-019-05365-y. Epub 2019 Jul 26.

PMID:
31346846
38.

Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'.

Mele G, Pastore D, Di Renzo N, Fragasso A, Guarini A, Mazza P, Musto P, Pavone V, Tarantini G, Curci P, Falcone AP, Mele A, Miccolis MR, Palazzo G, Palumbo G, Quinto AM, Reddiconto G, Rizzi R, Cascavilla N, Specchia G, Capalbo SF.

Leuk Lymphoma. 2019 Dec;60(14):3565-3568. doi: 10.1080/10428194.2019.1636989. Epub 2019 Jul 9. No abstract available.

PMID:
31286780
39.

Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study.

Vivaldi C, Fornaro L, Cappelli C, Pecora I, Catanese S, Salani F, Cacciato Insilla A, Kauffmann E, Donati F, Pasquini G, Massa V, Napoli N, Lencioni M, Boraschi P, Campani D, Boggi U, Caramella D, Falcone A, Vasile E.

Cancers (Basel). 2019 Jul 4;11(7). pii: E939. doi: 10.3390/cancers11070939.

40.

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.

Pietrantonio F, Morano F, Corallo S, Miceli R, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Bergamo F, Sartore-Bianchi A, Tampellini M, Racca P, Clavarezza M, Berenato R, Caporale M, Antista M, Niger M, Smiroldo V, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Giordano M, Petrelli F, Longarini R, Cinieri S, Falcone A, Zagonel V, Di Bartolomeo M, de Braud F.

JAMA Oncol. 2019 Jul 3. doi: 10.1001/jamaoncol.2019.1467. [Epub ahead of print]

41.

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.

Larocca A, Mina R, Offidani M, Liberati AM, Ledda A, Patriarca F, Evangelista A, Spada S, Benevolo G, Oddolo D, Innao V, Cangialosi C, Bernardini A, Musto P, Amico V, Fraticelli V, Paris L, Giuliani N, Falcone AP, Zambello R, De Paoli L, Romano A, Palumbo A, Montefusco V, Hajek R, Boccadoro M, Bringhen S.

Haematologica. 2019 Jun 27. pii: haematol.2019.220657. doi: 10.3324/haematol.2019.220657. [Epub ahead of print]

42.

Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable.

Ongaro E, Cremolini C, Rossini D, Corti F, Pagani F, Morelli L, Urbani L, Masi G, Sposito C, Filippi B, Borelli B, Zucchelli G, Moretto R, Boccaccino A, Solaini L, de Braud F, Mazzaferro V, Falcone A, Cucchetti A, Pietrantonio F.

ESMO Open. 2019 May 9;4(2):e000496. doi: 10.1136/esmoopen-2019-000496. eCollection 2019.

43.

Quantitative evidence for early metastatic seeding in colorectal cancer.

Hu Z, Ding J, Ma Z, Sun R, Seoane JA, Scott Shaffer J, Suarez CJ, Berghoff AS, Cremolini C, Falcone A, Loupakis F, Birner P, Preusser M, Lenz HJ, Curtis C.

Nat Genet. 2019 Jul;51(7):1113-1122. doi: 10.1038/s41588-019-0423-x. Epub 2019 Jun 17.

44.

Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells.

Orlandi P, Gentile D, Banchi M, Cucchiara F, Di Desidero T, Cremolini C, Moretto R, Falcone A, Bocci G.

Invest New Drugs. 2020 Feb;38(1):92-98. doi: 10.1007/s10637-019-00804-5. Epub 2019 Jun 1.

PMID:
31154566
45.

Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial.

Marmorino F, Falcone A, Cremolini C.

Oncotarget. 2019 Apr 19;10(29):2791-2792. doi: 10.18632/oncotarget.26870. eCollection 2019 Apr 19. No abstract available.

46.

AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer.

Del Re M, Crucitta S, Sbrana A, Rofi E, Paolieri F, Gianfilippo G, Galli L, Falcone A, Morganti R, Porta C, Efstathiou E, van Schaik R, Jenster G, Danesi R.

BJU Int. 2019 May 4. doi: 10.1111/bju.14792. [Epub ahead of print]

PMID:
31055861
47.

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.

Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators.

Lancet Oncol. 2019 Jun;20(6):849-861. doi: 10.1016/S1470-2045(19)30027-0. Epub 2019 Apr 16. Erratum in: Lancet Oncol. 2019 Jun;20(6):e293.

PMID:
31003911
48.

Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study.

Cremolini C, Benelli M, Fontana E, Pagani F, Rossini D, Fucà G, Busico A, Conca E, Di Donato S, Loupakis F, Schirripa M, Lonardi S, Borelli B, Ongaro E, Eason K, Morano F, Casagrande M, Fassan M, Sadanandam A, de Braud F, Falcone A, Pietrantonio F.

ESMO Open. 2019 Mar 8;4(2):e000489. doi: 10.1136/esmoopen-2019-000489. eCollection 2019.

49.

Interprofessional spiritual care in oncology: a literature review.

Puchalski CM, Sbrana A, Ferrell B, Jafari N, King S, Balboni T, Miccinesi G, Vandenhoeck A, Silbermann M, Balducci L, Yong J, Antonuzzo A, Falcone A, Ripamonti CI.

ESMO Open. 2019 Feb 16;4(1):e000465. doi: 10.1136/esmoopen-2018-000465. eCollection 2019.

50.

Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics.

Di Desidero T, Orlandi P, Fioravanti A, Alì G, Cremolini C, Loupakis F, Gentile D, Banchi M, Cucchiara F, Antoniotti C, Masi G, Fontanini G, Falcone A, Bocci G.

Biochem Pharmacol. 2019 Jun;164:94-105. doi: 10.1016/j.bcp.2019.04.001. Epub 2019 Apr 3.

PMID:
30953637

Supplemental Content

Loading ...
Support Center